Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weight-Loss drug wegovy tested as Hair-Pulling treatment

NCT ID NCT07282769

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a weekly injection of semaglutide (Wegovy), a drug used for weight loss and diabetes, can help people with trichotillomania (hair-pulling disorder). Ten adults aged 18-75 with daily hair pulling will receive the drug for several weeks. Researchers will measure changes in hair-pulling severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (Wegovy)
What this could lead to
If it works, this could point toward a new treatment option for trichotillomania, reducing the urge to pull hair.
What could go wrong
This is a very small, early-phase trial with only 10 people and no placebo group, so results may not be reliable or generalizable. Semaglutide can cause nausea, vomiting, and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women age 18-75; 2. Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13); 3. Hair pulling daily with urges to pull as the trigger in \>50% of the episodes of pulling; 4. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test; 5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence Exclusion Criteria: 1. Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull); 2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator; 3. History of seizures; 4. Myocardial infarction within 6 months; 5. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential; 6. A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator; 7. Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale); 8. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder; 9. Current skin picking disorder; 10. Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline; 11. Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed); 12. Previous treatment with semaglutide; 13. Use of any weight loss medications; 14. Body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23; 15. Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder; 16. Recent (30-day) use of illicit drugs except cannabis; 17. History of diabetes, and current medical or neurological illness precluding participation based on physician judgment; 18. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B; 19. History of pancreatitis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hair pulling are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.